Expanding Contracted Services through Strategic Alliances

「New preferred agreement signed with a major domestic pharmaceutical company」

「In the fiscal year ending March 2026, we newly signed a preferred agreement with one major domestic pharmaceutical company, bringing the total to 4 domestic pharmaceutical companies. Our strengthened sales activities targeting work from Europe and the United States, including the formation of a Global Study Team (GST) dedicated to overseas customers at our Safety Research Institute in November 2024, also paid off, and we obtained preferred-vendor certification from one global megapharma company in the fiscal year ending March 2026.」

「During the first half, we newly signed a preferred agreement with one domestic pharmaceutical company. We also strengthened sales activities targeting work from Europe and the United States, including by forming a Global Study Team (GST) dedicated to overseas customers at our Safety Research Institute in November 2024. As a result, we were certified as a preferred vendor by one global megapharma company during the first half.」

「In recognition of these initiatives, we signed preferred agreements with several pharmaceutical companies, under which work is preferentially outsourced to preselected CROs, leading to higher orders. In the fiscal year ending March 2024, we also received orders for initial due-diligence studies from several major overseas pharmaceutical companies toward preferred agreements.」

「Under this option agreement, Hokkaido University, TMS Co., Ltd. and Kanazawa University signed a joint research agreement in October 2023. Other matters have also progressed to the signing of memoranda of understanding and similar agreements, contributing to the out-licensing and in-licensing of drug-discovery seeds and technologies and to industry-academia collaboration.」

「Several major overseas pharmaceutical companies had been conducting due diligence toward new agreements since the start of the fiscal year ending March 2024, and in the third quarter we secured pilot orders from several companies.」

「Since the beginning of the current fiscal year, several major overseas pharmaceutical companies have stepped up due diligence toward new agreements, and we have begun accepting specific pilot studies.」

「In the fiscal year ending March 2023, we signed a new preferred agreement with a domestic pharmaceutical company in recognition of these initiatives, which has led to higher orders. Due diligence toward preferred agreements with several major overseas pharmaceutical companies is also now in full swing.」

「For the purpose of developing a novel intranasal vaccine, we signed a joint research agreement with the Faculty of Biology-Oriented Science and Technology at Kindai University in January 2023. In addition, in August 2022 we signed a business alliance agreement with Shionogi Pharma Co., Ltd., a development-oriented contract pharmaceutical manufacturer, to promote the manufacturing development of intranasal formulations and other products, strengthening our R&D structure with a view to commercialization.」

「The equity-method investment gain from SNBL PPD for the nine months ended December 31 was ¥864 million, compared with ¥538 million in the same period of the previous fiscal year.」

「We continue negotiations with overseas pharmaceutical companies concerning the out-licensing and co-development of multiple drug candidates.」

「Joint research with major pharmaceutical companies is also progressing steadily.」

「Joint research with major pharmaceutical companies is also progressing steadily.」

「Joint research with major pharmaceutical companies is also progressing steadily.」

「We continue negotiations with overseas pharmaceutical companies concerning the out-licensing and co-development of multiple drug candidates.」

「Meanwhile, Nose-to-Brain drug-delivery technology, which uses NDS to deliver drugs from the nose to the brain, is progressing. We are analyzing the mechanism by which drugs are actively transferred to central nervous system cells. We are currently analyzing imaging of drug transfer to the brain, while joint research with major pharmaceutical companies is also progressing steadily.」

「Joint research with major pharmaceutical companies is progressing steadily, and we are further deepening our analysis of drug transfer to the brain.」

「Joint research and feasibility studies with several major pharmaceutical companies are progressing steadily, and we are further deepening our analysis of drug transfer to the brain.」

「Joint research and feasibility-study agreements with several major pharmaceutical companies are progressing steadily, and we have obtained data that will enable us to move to the next stage. Following active presentations of these results at academic conferences and related sales activities, inquiries from major pharmaceutical companies in Japan and overseas have increased.」

「Research into Nose-to-Brain drug-delivery technology, an application of our Nasal Delivery System (NDS), has progressed steadily under joint research and feasibility-study agreements signed with several major pharmaceutical companies last year, and data enabling us to move to the next stage is emerging. In addition, inquiries from major pharmaceutical companies in Japan and overseas have increased as a result of active conference presentations and sales activities.」

「In the United States, we converted SNBL Clinical Pharmacology Center, Inc., whose main business was Phase I operations in Baltimore, Maryland, into a joint venture with Pharmaron Beijing Co., Ltd. in March of the previous year. The company became an equity-method affiliate, was renamed Pharmaron CPC, Inc., and continues to operate under the new structure.」

「SNBL PPD, the joint venture with Pharmaceutical Product Development LLC that operates our domestic clinical business, is steadily strengthening its organizational structure to respond quickly to the rapidly expanding global clinical-trial market, and both its organization and contract research agreements are growing steadily.」

「Our U.S. clinical business is now being operated under a new structure by Pharmaron CPC, Inc., an equity-method affiliate formed as a joint venture with Pharmaron Beijing Co., Ltd. in March of this year. The company was renamed from SNBL Clinical Pharmacology Center, Inc. in May of this year.」

「By making Pharmaron, which has significant potential and intends to expand its business in the clinical-trial field for small-molecule drugs, particularly in the U.S., including technologies for clinical trials using radioactive elements, our joint-venture partner, we can continue to enhance the enterprise value of SNBL CPC.」

「Our U.S. clinical business is deepening its partnership with the University of Maryland, Baltimore (UMB), while also actively pursuing collaborations with other CROs, leading to strong business expansion.」

「Our U.S. clinical business is deepening its partnership with the University of Maryland, Baltimore (UMB), while also actively pursuing collaborations with other CROs, leading to strong business expansion.」

「Our U.S. clinical business is deepening its partnership with the University of Maryland, Baltimore (UMB), and also began a collaboration with PPD last year, leading to active business expansion.」

「Pharmaceutical companies are increasingly reducing fixed research and development costs and using outsourcing in Japan and overseas. To address these new market opportunities, we will build alliances based on deeper relationships with existing customers and strengthen relationships of trust with them.」